Liver Proteins May Protect Brain Cells and Memory in Alzheimer's Mice

Liver-derived proteins may offer a new way to protect brain cells and improve memory in Alzheimer’s disease models, according to a study published in the journal Cell.

For decades, the blood-brain barrier (BBB) has been viewed primarily as a fortress—a restrictive gatekeeper that protects the central nervous system by blocking the vast majority of circulating substances.

While this barrier is essential for safety, it also presents a massive hurdle for modern medicine, as estimates suggest that more than 98% of small-molecule drugs and most biologics cannot cross it. This limitation has long stymied the development of effective therapies for neurological disorders.

New research suggests the barrier is less of a wall and more of a sophisticated, active transport interface. Scientists have discovered that the brain relies on specific proteins produced in the liver, adipose tissue, and intestines to maintain health. News-Medical reported that researchers identified a specific pathway involving apolipoprotein A1 (APOA1) that could potentially be harnessed to combat neurodegeneration.

The liver-brain connection

The study, conducted by a collaborative team including the Gladstone Institutes, the University of California, San Francisco, the Buck Institute for Research on Aging, and Emory University, utilized a bioorthogonal proteomics approach to map how proteins enter the brain. By labeling plasma proteins and injecting them into mice, the researchers tracked exactly which substances crossed the blood-brain barrier.

UCSF Scientists Just Discovered a Hidden Supply Line From the Liver to the Brain — Nexus Futura

The team identified 191 plasma proteins that interacted with the brain’s vasculature, with 92 of those successfully crossing into the brain parenchyma. The researchers found that these transported proteins were predominantly sourced from the liver, intestine, and fat tissues. They were largely enriched for enzymes involved in lipid and carbohydrate metabolism, as well as carrier proteins.

Among these, APOA1 stood out for its specific behavior. While other proteins like alpha-1 antitrypsin (SERPINA1) tended to enter microglia, APOA1 preferentially accumulated in astrocytes. This “hand-off” mechanism involves a receptor-mediated process where APOA1 is taken up by brain endothelial cells via scavenger receptor class B type 1 (SR-B1) and then directed toward astrocytes through the ATP-binding cassette transporter A1 (ABCA1).

Restoring synaptic function

The implications for Alzheimer’s disease are tied to how this transport mechanism fails. In 5xFAD mouse models—which mimic early-stage Alzheimer’s—the researchers observed selective changes in protein transport. Specifically, the uptake of the neuroprotective APOA1 decreased in astrocytes, while the uptake of SERPINA1 increased in microglia.

To test if they could reverse this, the scientists increased the production of hepatic APOA1 in the mice using an adeno-associated virus serotype 8 (AAV8) vector. The results were measurable across several biological markers:

Biological Metric	Observed Change in APOA1-Treated Mice
Astrocytic lipid accumulation	Decreased
Brain interleukin-1 beta (IL-1β)	Decreased
Hippocampal dentate gyrus plaque burden	Decreased
Synaptic density (Hippocampus/Cortex)	Increased

Beyond the cellular level, the treatment had tangible effects on behavior. The mice showed reduced hyperactivity and improved spatial memory, evidenced by a better preference for a novel arm in behavioral tests. They also demonstrated improved novel-object preference, though changes in novel-place recognition were not significant.

Limits of the current findings

While the results are promising, the scientific community must approach these findings with a measured perspective. The study primarily utilized mouse models, and it remains an open question whether these specific protein transport pathways and the therapeutic effects of increased APOA1 will translate to humans. There is also uncertainty regarding whether these treatments would remain effective during the more advanced, late-stage phases of Alzheimer’s disease.

The researchers said that the proteomics screen employed might not have captured every single protein involved in these processes. While the APOA1 treatment helped regulate lipids in astrocytes and improved synaptic markers, the study found that direct APOA1 treatment alone did not reproduce these neuronal benefits; the effect was dependent on the astrocytes' ability to mediate cholesterol transport.

The findings published in Cell establish that the blood-brain barrier is an active, selective interface rather than a simple filter. This shifts the focus of neurodegenerative research from merely trying to “break through” the barrier to understanding how to optimize the natural, vital communication between the body’s metabolic organs and the brain.

The researchers concluded that the liver-plasma-brain APOA1 pathway represents a potential therapeutic target for future neurological interventions.

Worth a look